Attitude Toward Safety in Needs to Change
A co-founder of the company ApconiX, based in Alderley Park, has revealed his view that attitude towards safety in pre-clinical cancer drug development needs to change.
“There is still huge unmet need in effective cancer treatment and it can be tempting for companies researching new drugs to focus mainly on efficacy data with safety issues relegated to secondary importance,” explained Dr Richard Knight of ApconiX. “However, an improved safety profile is not only an important way to reduce the high rate of drug failure, it can also expedite clinical trials and, above all, it’s the best thing to do for patients.”
Read more here: Attitude toward safety in cancer drug development needs to change, says ApconiX co-founder
Share This Story, Choose Your Platform!
Dr Richard Knight PhD, ERT. A co-founder of ApconiX, Richard is an expert toxicologist with more than 20 years of drug development experience gained in AstraZeneca, where he was part of the Drug Safety and Oncology Leadership Teams. Richard has worked on projects in multiple therapy areas involving small molecules, biologics, proteins and oligonucleotides. He has an in-depth understanding of drug discovery and drug development and has been directly involved in bringing over 35 new candidate drugs to clinical trials and 6 to marketing approval. He uses his extensive experience to bring an innovative, science-led and pragmatic approach to the design and delivery of nonclinical safety programmes.